Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by DBV Technologies S.A.

< Previous 1 2 Next >
DBV Technologies to Participate in Upcoming AAAAI 2024 Congress
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Present New Data at ACAAI 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Receives Requested Feedback from FDA on Protocol Design Elements for COMFORT Safety Studies and Reports Third Quarter 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Report Third Quarter 2023 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Announces Appointment of Virginie Boucinha as Chief Financial Officer
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Monthly information regarding the total number of voting rights and total number of shares of the Company as of September 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Receives Feedback from FDA on Design Elements for Viaskin Peanut Safety Studies and Reports Second Quarter and Half-Year 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Report First Half 2023 Financial Results and Provide a Corporate Update
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Monthly information regarding the total number of voting rights and total number of shares of the Company as of June 30, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Monthly information regarding the total number of voting rights and total number of shares of the Company as of May 31, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Participate in Upcoming EAACI Congress 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Announces New England Journal of Medicine Publication of Phase 3 EPITOPE Trial Data Evaluating Viaskin™ Peanut in Toddlers
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Participate in Upcoming Investor Conference
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Reports First Quarter 2023 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Outlines Regulatory Path for Viaskin Peanut in Children 1 – 3 Years After Receiving Pre-BLA Responses from FDA
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Announces Results of its 2023 Ordinary and Extraordinary General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
Ordinary and Extraordinary General Meeting of April 12, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Update
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Announces First Patient Screened in VITESSE Phase 3 Clinical Trial in Peanut-Allergic Children 4 – 7 Years Old
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies announces filing of 2022 Annual Report on Form 10-K and 2022 Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies Reports Full Year 2022 Financial Results and Business Update
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Report Full Year 2022 Financial Results and Business Updates on March 2, 2023
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
DBV Technologies to Participate in Upcoming AAAAI 2023 Congress
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.